Medtronic plc (Dublin,Ireland;www.medtronic.com) has entered into a set of definitive agreements for the acquisition of EOFlow Co,Ltd. (Seongnam,South Korea; www.eoflow.com),which manufactures the EOPatch device-a tubeless, wearable and fully disposable insulin delivery device.

With the integration of EOFlow and Medtronic’s proprietary Meal Detection Technology algorithm and next-generation continuous glucose monitor(CGM), Medtronic aims to cater to a larger diabetic population.

This will allow the company to provide varied insulin delivery options,catering to individual needs and preferences, regardless of their treatment stage.